A079 - REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA
Shafqat Inam, Sean Apap Mangion, Victoria Potter, et al.
Conclusions: We describe the clinical features of ICANS in our real-world cohort of patients receiving standard of care CD19 CAR T-cells, and demonstrate the feasibility of anakinra in combination with dexamethasone for treatment ICANS that is severe or not initially responsive to high dose steroids.
Francis Ayuk, Anita Badbaran, Carolina Berger, et al.
Conclusions: Despite the relatively small patient number, our data emphasize the importance of monitoring CAR-T concentrations after infusion and indicate an association with response and side effects. CAR-T cell proliferation appears to bounce back after treatment with dexamethasone.
Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, et al.
Conclusions: In this prospective single center pilot study, blood samples of emerging CRS showed a reduction of Tregs frequencies and absolute numbers compared to no-CRS patients. After clearance of CRS, Tregs frequencies increased to values of no-CRS patients. Therefore, investigation of Treg frequencies as a predictive marker for CRS should be further investigated. However, future studies are needed to validate these findings in a larger cohort.
Nora Moehn, Viktoria Bonda, Mike P. Wattjes, et al.
Conclusions: Neurotoxicity is a feared complication of CD19 CAR T cell therapy and initial symptoms can be very subtle. Our longitudinal examinations in 11 patients revealed specific clinical symptoms of ICANS in 2 patients without relevant radiological abnormalities. Further studies with higher numbers of patients including a structured and detailed neurological examination are required to uncover CD19 CAR T cell-related neurotoxicity and its especially pathogenesis.